ClinicalTrials.gg
RecruitingNCT06967272Updated Aug 22, 2025

PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

A Phase 2 interventional study of Oral hexavalent reassortant rotavirus attenuated live vaccine and Oral hexavalent reassortant rotavirus attenuated live vaccine in Rotavirus Gastroenteritis, sponsored by Sinovac Life Sciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Study summary

The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.

Read the detailed description

The Phase II clinical trial is a randomized, double-blind, active-controlled study conducted in healthy infants to evaluate the immunogenicity and safety of the investigational vaccine. The investigational vaccine is available in both high-dose and low-dose formulations. The control vaccine is the orally administered pentavalent reassortant rotavirus attenuated live vaccine (Vero Cells) produced by Merck Sharp \& Dohme Corp.

This study plans to recruit 400 infants aged 6 to 12 weeks. All participants will be randomly assigned to the low-dose investigational group, high-dose investigational group, and active-controlled group, respectively.The immunization schedule for both the investigational vaccine and controlled vaccine consists of three doses administered at 28-day intervals.

Blood samples will be collected at predefined time points to evaluate the immunogenicity of the investigational vaccine. Adverse events (AEs) will be collected for all participants from the first vaccination until 42 days after the last dose, while serious adverse events (SAEs) and adverse events of special interest (AESIs) will be monitored for 12 months.

A safety monitoring sub-cohort will be established, with stool samples collected daily for 14 days after each vaccination to assess vaccine virus shedding, duration and patterns of viral shedding, potential reassortment and reversion to virulence of the rotavirus vaccine strains

02

Conditions studied

  • Rotavirus Gastroenteritis

Browse trials for

Keywords

  • Phase II
  • Immunogenicity
  • Safety
  • Randomized Controlled Trial
  • Rotavirus gastroenteritis
  • Vaccine
03

In context

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

This study's planned enrollment of 400 is above the median of 136 across 164 interventional studies indexed under Gastroenteritis.

Browse Gastroenteritis studies →

Lead sponsor

Sinovac Life Sciences Co., Ltd. is the lead sponsor of 26 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants aged 6 to 12 weeks.
  2. The legal guardian(s) is/are capable of understanding and voluntarily signing the form.
  3. The legal guardian(s) is/are willing and able to comply with all follow-up visits, sample collection, vaccination, and other study procedures.
  4. Able to provide valid legal identification documents.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with any rotavirus vaccine.
  2. History of rotavirus infection.
  3. Gestational age \<37 weeks or ≥42 weeks at birth.
  4. History of dystocia, neonatal asphyxia requiring resuscitation, or neurological impairment at birth.
  5. Known to any vaccine component (e.g., urticaria, dyspnea, angioedema).
  6. Current diarrhea, vomiting, or other gastrointestinal disorders; gastroenteritis or any acute/chronic illness exacerbation within 7 days prior to vaccination; ongoing antibiotic/antiviral therapy.
  7. History of intussusception or chronic gastrointestinal diseases, including congenital malformations predisposing to intussusception (e.g., Meckel's diverticulum).
  8. Congenital malformations, developmental disorders, genetic defects, severe malnutrition, , or significant chronic conditions (e.g., Down syndrome, diabetes, sickle cell anemia, neurological disorders, Guillain-Barré syndrome).
  9. or immunodeficiency diseases (including but not limited to asplenia, functional asplenia, infection).
  10. Household members with immunodeficiency/ or undergoing/scheduled for immunosuppressive/cytotoxic therapy.
  11. Coagulation disorders (e.g., clotting factor deficiencies, abnormalities).
  12. Immunosuppressive therapy for ≥14 days post-birth (prednisone ≥2mg/kg/day or equivalent), immunomodulatory/cytotoxic therapy, or planned use during the study.
  13. History of severe neurological/psychiatric disorders (e.g., epilepsy, non-febrile seizures, convulsions) or relevant family history.
  14. Postnatal administration of immunoglobulins/blood products (except immunoglobulin) or planned use during the study.
  15. Previous participation in other drug/vaccine studies or planned use during this study.
  16. Receipt of within 14 days or subunit/inactivated vaccines within 7 days prior to enrollment.
  17. Axillary temperature ≥38.0°C within the past 3 days.
  18. Fever on scheduled vaccination day (axillary temperature >37.0°C; measured ≥30 minutes post-feeding).
  19. Currently or planning to participate in other vaccine or drug clinical trials.
  20. Any other factors that the investigator deems unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Low dose

    The experimental vaccine will be administered in three doses, with a 28-day interval between each dose.

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Experimental
    High dose

    The experimental vaccine will be administered in three doses, with a 28-day interval between each dose.

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Active comparator
    Control

    The controlled vaccine will be administered in three doses, with a 28-day interval between each dose.

    Biological: Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)

Interventions

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

  • BiologicalOral pentavalent reassortant rotavirus attenuated live vaccine (controlled)

    The controlled vaccine three doses administered orally

06

What researchers measure

Primary outcomes

  1. Evaluate the immunogenicity of the investigational vaccine at different doses

    The seroconversion rate of IgA antibodies against vaccine-type rotavirus in serum

    Time frame: 28 days after the full vaccination course

  2. Evaluate the safety of the investigational vaccine at different dose

    Incidence of adverse events/reactions

    Time frame: 0 day after the first dose till 42 days after the last dose

Secondary outcomes

  1. Evaluate the immunogenicity of the investigational vaccine at different doses

    The positivity rate of serum anti-vaccine-type rotavirus IgA antibodies

    Time frame: 28 days after the full vaccination course

  2. Evaluate the immunogenicity of the investigational vaccine at different doses

    The geometric mean concentration (GMC) of serum anti-vaccine-type rotavirus IgA antibodies

    Time frame: 28 days after the full vaccination course

  3. Evaluate the immunogenicity of the investigational vaccine at different doses

    The geometric mean increase (GMI) of serum anti-vaccine-type rotavirus IgA antibodies

    Time frame: 28 days after the full vaccination course

  4. Evaluate the immunogenicity persistence of the investigational vaccine at different doses

    The geometric mean concentration (GMC) of serum anti-vaccine-type rotavirus IgA antibodies

    Time frame: 12 months after the full vaccination course

  5. Evaluate the immunogenicity persistence of the investigational vaccine at different doses

    The positivity rate of serum anti-vaccine-type rotavirus IgA antibodies

    Time frame: 12 months after the full vaccination course

  6. Evaluate the safety of the investigational vaccine at different dose

    Incidence of adverse events/reactions

    Time frame: 0-30 minutes after each dose

  7. Evaluate the safety of the investigational vaccine at different dose

    Incidence of adverse events/reactions

    Time frame: 0-14 days after each dose

  8. Evaluate the safety of the investigational vaccine at different dose

    Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: The first dose to 12 months after full vaccination

  9. Evaluate the fecal shedding of investigated vaccine strain after vaccination

    The shedding rate of the rotavirus vaccine strain in the stool.

    Time frame: 0-14 days after each dose

  10. Evaluate the fecal shedding of investigated vaccine strain after vaccination

    The shedding duration of the rotavirus vaccine strain in the stool.

    Time frame: 0-14 days after each dose

  11. Evaluate the reassortment and reversion of the rotavirus vaccine strain in stool samples after vaccination

    The incidence of reassortment and reversion of the rotavirus vaccine strain in stool samples.

    Time frame: 0-14 days after each dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jun 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2025
First posted
May 13, 2025
StartActual
Jan 20, 2025
Primary completionEst.
Jun 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967272
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Jan 20, 2025
Primary completion
Jun 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Aug 22, 2025

Study contacts

Yeqing Tong
Contact
63382251@qq.com
+86-13971078410

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion